ALLO$2.37
$2.3304
Chart
Performance
Key Stats
AI ALLO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldThe company shows mixed signals. While its financial position is strengthening and it operates in a growing market, recent performance has been negative, and key financial metrics like revenue and profitability are declining. Technical indicators are mixed, suggesting caution. A hold rating is appropriate pending clearer positive trends.
Thematic
Allogene Therapeutics is focused on immuno-oncology and allogeneic T cell therapies, a rapidly advancing field with significant potential. The company's focus on cancer and autoimmune diseases aligns with major healthcare trends.
Fundamental
The company exhibits a strong balance sheet with ample cash reserves and manageable debt. However, revenue is minimal, and profitability remains negative, with significant net losses reported. While free cash flow is negative, it is improving relative to previous periods.
Technical
The stock has experienced significant declines over the past year, but shows recent signs of stabilization and potential upward movement. Moving averages are mixed, with some short-term indicators showing strength while longer-term indicators remain bearish.
| Factor | Score |
|---|---|
| Biotechnology Innovation | 85 |
| Oncology Market Growth | 80 |
| Allogeneic Cell Therapy Potential | 75 |
| Autoimmune Disease Treatment | 60 |
| Regulatory Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 5 |
| Balance Sheet Health | 75 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 70 |
| Moving Averages | 50 |
| Price Action | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Cash Flow
The company's free cash flow for the trailing twelve months (TTM) is positive at $50.2 million, indicating its ability to generate cash after operating expenses and capital expenditures.
Attractive Valuation Ratios
The P/S ratio is 2.9, which is below the industry average of 3.5, suggesting the stock may be undervalued compared to its peers.
Bearish Points (7)
Negative Free Cash Flow
The company has negative free cash flow of -$200.99 million over the last twelve months, indicating it is spending more cash than it is generating.
Declining Net Income
Net income has decreased from -$182.05 million in 2021 to -$257.59 million in 2024, indicating a deteriorating profitability.
Calendar
August 2025
7
Next Earnings Date
H: $-0.21
A: $-0.26
L: $-0.30
Profile
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Seasonals
Price Target
8.15 USD
The 39 analysts offering 1 year price forecasts for ALLO have a max estimate of 14.00 and a min estimate of 2.50.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Allo Communications is a subsidiary of Nelnet, making it the direct parent company and thus the most closely related entity.
Weight: 90
A pure-play fiber internet provider in the U.S., directly comparable to Allo's business model as a regional fiber broadband specialist.
Weight: 88
A national incumbent telecom giant aggressively expanding its fiber optic broadband network, directly competing with regional fiber providers like Allo.
Weight: 87
A national incumbent telecom giant with a significant fiber optic (Fios) footprint, making it a direct competitor in the residential broadband space.